| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10549-017-4435-X |
| P8608 | Fatcat ID | release_brxkgdevhva73drptdmsiaweii |
| P932 | PMC publication ID | 6886242 |
| P698 | PubMed publication ID | 28780701 |
| P50 | author | David Gorski | Q16729388 |
| P2093 | author name string | Cecilia L Speyer | |
| Sudeshna Bandyopadhyay | |||
| Miriam A Bukhsh | |||
| Waris S Jafry | |||
| Rachael E Sexton | |||
| P2860 | cites work | The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation | Q24678674 |
| Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling | Q27851446 | ||
| Microtubules as a target for anticancer drugs | Q28253993 | ||
| Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies | Q29617680 | ||
| ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. | Q30176115 | ||
| A functional screen for genes inducing epidermal growth factor autonomy of human mammary epithelial cells confirms the role of amphiregulin | Q30999913 | ||
| A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma | Q33616544 | ||
| A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? | Q34104378 | ||
| Triple Negative Breast Cancer - An Overview | Q34274285 | ||
| Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1. | Q34525011 | ||
| Triple-negative breast cancer: clinical features and patterns of recurrence | Q34658655 | ||
| Standard of care and promising new agents for triple negative metastatic breast cancer | Q34774884 | ||
| Oncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast cancer | Q35007438 | ||
| Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer | Q35122078 | ||
| Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. | Q35757521 | ||
| Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes | Q37269261 | ||
| Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer | Q37431333 | ||
| Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer | Q37502074 | ||
| Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells | Q37626431 | ||
| The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells | Q37731451 | ||
| The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer | Q38295108 | ||
| Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. | Q39591407 | ||
| Activation of a nuclear factor kappaB/interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells | Q40099297 | ||
| Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression | Q42009322 | ||
| Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features | Q42504459 | ||
| Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. | Q43512515 | ||
| Bcl-2 and BLIMP-1 expression predict worse prognosis in gastric diffuse large B cell lymphoma (DLCBL) while other markers for nodal DLBCL are not useful. | Q43816514 | ||
| Enhanced endogenous type I interferon cell-driven survival and inhibition of spontaneous apoptosis by Riluzole | Q44597587 | ||
| Riluzole induces apoptotic cell death in human prostate cancer cells via endoplasmic reticulum stress. | Q45968193 | ||
| Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells | Q46493494 | ||
| Protein kinase C negatively regulates Akt activity and modifies UVC-induced apoptosis in mouse keratinocytes | Q46843527 | ||
| A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C. | Q55034186 | ||
| Riluzole | Q56483801 | ||
| The problem of synergism and antagonism of combined drugs | Q73248616 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell growth | Q189159 |
| paclitaxel | Q423762 | ||
| P304 | page(s) | 407-419 | |
| P577 | publication date | 2017-08-05 | |
| P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
| P1476 | title | Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer | |
| P478 | volume | 166 |
| Q64276226 | ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia |
| Q58098917 | Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer |
| Q92705179 | Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma |
Search more.